Medifast, Inc.

Medifast, Inc. (MED) Market Cap

Medifast, Inc. has a market capitalization of $109.3M.

Price: $9.83

-0.08 (-0.81%)

Market Cap: 109.30M

NYSE · time unavailable

CEO: Nicholas Johnson

Sector: Industrials

Industry: Specialty Business Services

IPO Date: 1993-12-30

Website: https://medifastinc.com

Medifast, Inc. (MED) - Company Information

Market Cap: 109.30M|Sector: Industrials

Company Profile

Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.

Analyst Sentiment

50%
Hold

From 1 Active Polls

1Y Forecast: $12.00

▲ +22.1% Potential Upside

Consensus Target Metrics

Low Bound

$12

Median

$12

High Bound

$12

Average

$12

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$12.00
▲ +22.08% Upside
Low Target
$12.00
22% Risk
Median Target
$12.00
22% Mid
High Target
$12.00
22% Max
Consensus
Hold
4 / 12 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)109112117150154148193209230
Enterprise Value ($M)545745636670118112141
Price to Earnings Ratio (P/E)-5.40-13.41-1.62-16.2715.27-48.1462.9347.85-7.01
Price/Earnings-to-Growth Ratio (PEG)-10.62
Price to Sales Ratio (P/S)0.321.471.561.681.461.281.621.491.36
Price to Book Ratio (P/B)0.550.570.590.700.710.700.921.011.12
Price to Free Cash Flow Ratio (P/FCF)-74.30-134.15-17.7113.98-32.4778.33-26.6527.2520.66
Enterprise Value to Sales (EV/Sales)0.750.600.700.620.610.990.800.84
Enterprise Value to EBITDA (EV/EBITDA)8.5036.79-15.3879.229.5118.5226.4423.40-18.61
Debt to Equity Ratio-8.740.080.080.060.060.070.080.090.09

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MEDIFAST INC (MED) — Investment Overview

🧩 Business Model Overview

MEDIFAST operates a structured weight-management ecosystem anchored by branded meal products and a coach-led service model. Customers purchase meal replacement products bundled into program “plans,” typically supplied through an ongoing ordering pattern (subscription-like replenishment) rather than one-off retail purchases. The company’s value chain includes (1) sourcing and manufacturing branded weight-management food, (2) marketing and fulfillment through direct channels, and (3) sustained customer engagement through coaching and program structure that reinforces adherence. This creates a recurring consumption loop: meal-plan delivery supports continued participation, and participation sustains continued product orders.

💰 Revenue Streams & Monetisation Model

Revenue primarily derives from the sale of meal replacement products and program-related offerings. Monetisation is supported by repeat purchasing and multi-week program structures, which tend to convert product demand into a more recurring revenue profile than traditional packaged-food models. Margin drivers include (i) product mix across higher-margin SKUs within meal plans, (ii) supply-chain and manufacturing efficiency at scale, (iii) fulfillment and distribution economics, and (iv) customer retention and order cadence that reduce the effective cost of acquiring and servicing cohorts. Because the program depends on sustained adherence, changes in churn and re-order behavior materially influence medium-term revenue visibility and operating leverage.

🧠 Competitive Advantages & Market Positioning

MEDIFAST’s moat is best characterized as a combination of switching costs and an integrated ecosystem—customers experience meaningful friction leaving the program due to established routines, meal-plan compatibility, and reliance on coaching/accountability. The company also benefits from a community/coaching distribution dynamic: independent coaches and program engagement can create referral-driven awareness and lower customer acquisition friction compared with purely digital or purely retail competitors. While this is not a classic “network effects” platform in the software sense, the coaching model can function like a network that supports recruitment and retention, reinforcing participation.

Competitive benchmarking (primary peers):
Nutrisystem (managed weight-loss meal plans sold through direct channels and retail partnerships): competitive set emphasizes packaged program foods, but generally lacks the same depth of coach-led engagement.
WeightWatchers (WW) (subscription behavioral program): competes on ongoing membership services and point-based adherence, putting pressure on customer spend when users compare value versus product-based plans.
Herbalife Nutrition (independent distributor model with nutrition products): competes through a coach/distributor-led ecosystem, but differs in its program structure and meal-plan specificity.

MEDIFAST’s positioning differentiates through the tightly bundled meal-plan system plus coaching-led adherence, rather than relying solely on either retail product availability (as in many CPG approaches) or a platform-driven membership model without a comparable proprietary meal regimen.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, MEDIFAST’s growth potential is linked to durable demand for weight management and metabolic health services, including:

  • Secular obesity and chronic weight-management demand: Persistent prevalence drives sustained consumer need for structured, supported programs rather than short-duration diets.
  • Shift toward managed programs with ongoing replenishment: Meal-plan ecosystems can convert health intent into recurring purchases via scheduled consumption.
  • Program expansion and product line refinement: Continued optimization of plan structures and SKU mix can support higher customer value per participant while maintaining adherence.
  • Operational scale and retention compounding: As cohorts repeat orders, fixed costs are spread over a larger revenue base, supporting operating leverage when churn remains controlled.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: Nutrition, labeling, and claims oversight can affect marketing practices and product communications.
  • Competitive intensity and promotional pricing: Direct competitors and larger membership programs can pressure customer acquisition costs and customer value.
  • Coach/distributor ecosystem health (channel dependency): Any structural weakness in recruitment, engagement, or retention of coaches can impair customer acquisition and re-order momentum.
  • Product supply-chain and input cost volatility: Ingredient costs, manufacturing constraints, and logistics disruptions can change gross margin trajectory.
  • Customer churn and adherence variability: Because the model relies on continued participation, changes in re-order behavior can reduce revenue visibility.
  • Litigation and product quality risk: As a food producer and brand owner, the business faces ongoing quality assurance and legal exposure.

📊 Valuation & Market View

The market for weight-management program companies typically values the business on a blend of revenue growth, gross margin durability, and the sustainability of operating leverage. Common reference points include EV/EBITDA for established profitability and P/S for scenarios where investors emphasize recurring revenue quality and long-term margin expansion. Key valuation drivers generally include (i) retention signals and order cadence (proxying recurring economics), (ii) gross margin performance driven by product mix and manufacturing efficiency, and (iii) operating expense discipline tied to customer acquisition and servicing costs.

🔍 Investment Takeaway

MEDIFAST’s long-term investment case rests on an integrated weight-management ecosystem where branded meal-plan products and coaching-led adherence create meaningful switching friction. The company’s competitive position is reinforced by repeat purchasing dynamics and operational scale, offering a plausible path to durable cash generation if retention remains resilient and product and channel execution hold. The core watchpoints are regulatory/compliance execution, channel strength, and the ability to maintain margin and cohort economics amid competitive pressure.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MED.

zacks.com2026-07-29

Medifast Stock to Post Q2 Earnings: What Investors Should Know

MED's Q2 results are likely to face continued pressure from GLP-1 adoption and a smaller coach base, while productivity gains and cost actions may have helped offset some challenges.

zacks.com2026-07-27

Medifast (MED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Medifast (MED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

businesswire.com2026-07-20

Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026 on Monday, August 3, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The.

zacks.com2026-07-20

Will Medifast's Trilivy Launch Unlock a New Growth Chapter?

Medifast's Trilivy expands beyond weight management with metabolic health support, personalized coaching and a structured three-phase journey.

businesswire.com2026-07-17

Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transf.

zacks.com2026-06-24

Medifast (MED) Loses 18.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Medifast (MED) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

globenewswire.com2026-06-11

What Science-Backed Subscription Health Programs Measure Differently

The weight loss and weight management market was valued at $31.07 billion in 2025  A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimed DXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scale Study completion rates carry significant weight in how research findings should be interpreted BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically studied," "science-backed," "proven," and "evidence-based" appear across a wide spectrum of programs, from programs with published randomized controlled trials to those with ingredient-level pilot data.

globenewswire.com2026-06-11

Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management

OPTAVIA's clinical program reduces visceral fat 14% and retains 98% lean mass, directly addressing the metabolic impact of perimenopause and menopause.

zacks.com2026-06-03

Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

zacks.com2026-06-02

Is MEDIFAST (MED) Stock Outpacing Its Consumer Staples Peers This Year?

Here is how Medifast (MED) and New York Times Co. (NYT) have performed compared to their sector so far this year.

businesswire.com2026-05-26

Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain active.

globenewswire.com2026-05-21

Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes

70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research identifying additional counseling and support as key for those showing lower early progress (Coleman CD, et al.

globenewswire.com2026-05-21

The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do

A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who attempted the program without coaching support (Arterburn LM, et al., 2019) Higher retention in a weight management program is directly correlated with more significant weight loss outcomes, per a 2024 systematic review and meta-analysis OPTAVIA coaches complete a program-specific education curriculum and must pass a certification exam before supporting participants Independent research commissioned by OPTAVIA found that 96% of Americans recognize lifestyle changes are essential for weight loss and management, yet only 17% feel confident they can manage it alone BALTIMORE, MD, May 21, 2026 (GLOBE NEWSWIRE) -- OPTAVIA, a science-backed, coach-guided comprehensive metabolic health system, is built around a core principle: that structured human support changes outcomes.

globenewswire.com2026-05-15

Peer-Reviewed Research Is Redefining Weight Loss Program Standards

The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the category Randomized controlled trials control for the lifestyle variables and selection bias that self-reported program data cannot account for, making them the standard for evaluating whether a weight loss program itself is driving outcomes Body composition is the breakdown of fat, lean mass, and bone. It shows what weight loss is actually made up of, a distinction that scale weight alone cannot capture A coach can address the specific barriers that may cause program adherence to stall, providing an additional support compared to digital trackers and tools BALTIMORE, MD, May 15, 2026 (GLOBE NEWSWIRE) -- Client experiences and peer-reviewed research are two pillars of evidence that, at their best, reinforce each other.

globenewswire.com2026-05-15

Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation

Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019) Structured plans, habit building, and dedicated coach support work together to produce body composition outcomes that reflect the quality of weight loss, not just its quantity (Arterburn LM, et al.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"MED reported Q1 2026 revenue of $76.0M and net loss of $(2.1)M (EPS: $(0.19)). On a YoY basis, revenue fell from $115.7M in Q1 2025 to $76.0M in Q1 2026 (-34.3% YoY), while net income deteriorated from a $(0.8)M loss to a $(2.1)M loss. QoQ, revenue edged down from $75.1M in Q4 2025 to $76.0M (+1.2% QoQ), but profitability remained weak: net loss widened from $(18.1)M (Q4 2025) to $(2.1)M (Q1 2026). Margin trends were mixed. Gross margin slightly improved to 68.1% (from 69.4% in Q4 2025), but operating margin stayed negative at -4.3% and net margin remained at -2.8% (vs -24.1% in Q4 2025). Cash flow quality improved meaningfully: operating cash flow was positive at $0.26M and free cash flow was about $(0.84)M. Balance sheet resilience looks solid with $71.5M cash and total equity of $197.7M; leverage remains low with net debt of approximately -$55.4M (net cash). Total shareholder returns: the stock price is $10.96 with 1Y change of -9.8%, and no dividend is reported. Without buyback data, capital returns appear negative, reducing the overall score."

Revenue Growth

Neutral

Revenue declined -34.3% YoY (115.7M in Q1’25 to 76.0M in Q1’26) and was roughly flat QoQ (+1.2% from Q4’25). The longer-run direction over the 4 quarters is downward.

Profitability

Neutral

Despite gross margin near ~68–70%, profitability is still negative. Net margin improved vs Q4’25 (-2.8% vs -24.1%) but remains loss-making. EPS improved to -0.19 from -1.65 QoQ, yet YoY net income worsened (from -0.8M loss to -2.1M loss).

Cash Flow Quality

Caution

Operating cash flow turned positive in Q1’26 at $0.26M, but free cash flow was still negative at about $(0.84)M after capex. No dividends are paid; financing outflows appear limited.

Leverage & Balance Sheet

Positive

Liquidity is strong with $71.5M cash and equity of $197.7M. Net debt is deeply negative (~-55.4M), indicating net-cash positioning. Total assets slightly declined QoQ (257.0M to 252.0M).

Shareholder Returns

Neutral

1Y price change is -9.8%, indicating negative capital appreciation. No dividend yield is reported, and buyback information is not available in the provided dataset—total return looks weak.

Analyst Sentiment & Valuation

Caution

Consensus price target is $12 vs current price $10.96 (modest upside). Valuation ratios are not consistently meaningful here due to net losses and negative/irregular cash flow measures.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Medifast’s Q1 2026 shows early stabilization signals in a GLP-1-disrupted weight-loss market, but the results remain loss-making and coach-count shrink continues. Revenue was $76M (-34.3% YoY), reflecting a -44.9% decline in active earning coaches to ~14,000. Offsetting that, revenue per active coach rose 19.2% to $5,432, with coach productivity up 19% YoY (+16% sequential), driven by more clients per coach (not larger orders) and improved length of stay. Gross margin fell to 68.1% (down 470 bps YoY) due to fixed-cost leverage loss, though SG&A as a % of revenue improved 150 bps largely from lower marketing spend and a one-time Maryland distribution center sale gain. Management reconfirmed FY26 guidance (revenue $270M-$300M; loss per share -$1.05 to -$2.75) and guided that profitability improvements should start in Q4 2026 after launching the new metabolic system planned for July, with >$30M future savings targeted under the 3.0 cost structure realignment.

AI IconGrowth Catalysts

  • First sequential quarterly revenue growth in three years driven by improved coach effectiveness in acquiring new clients
  • Second consecutive quarter of year-over-year coach productivity gains: +19% YoY and +16% sequential
  • Client referral engine strengthened: March closed with record-high % of new clients from referrals; participating coaches show 2x higher client acquisition rates
  • Planning to launch a new comprehensive metabolic system at next coach convention in July; full rollout later in 2026
  • Metabolic synchronization plan outcomes highlighted: 14% visceral fat reduction in 16 weeks and 98% lean mass retained; coach-assisted outcomes up to 10x weight loss and 17x fat loss vs self-directed

Business Development

    AI IconFinancial Highlights

    • Revenue: $76.0M, -34.3% YoY (primarily lower active earning coaches); EPS within guidance (exact expectation comparisons not stated)
    • Active earning coaches: ~14,000, -44.9% vs 2025 (decline attributed to rapid GLP-1 adoption and re-structuring into executive director organizations)
    • Revenue per active earning coach: $5,432, +19.2% YoY
    • Gross profit: $51.8M, -38.6% YoY; gross margin 68.1% vs 72.8% in 2025 (-470 bps YoY) due to loss of leverage on fixed costs
    • SG&A: $55.1M, -35.6% YoY; SG&A as % of revenue down 150 bps
    • SG&A as % revenue decomposition: ~470 bps decreased company-led marketing-related expenses and ~240 bps one-time gain from sale of Maryland distribution center (partially offset by ~620 bps loss of leverage on fixed costs from lower volume)
    • Operating loss: -$3.3M; operating margin -4.3%, 320 bps better than year-earlier
    • Other income: $1.4M, -24.3% YoY (unrealized gains on LifeMD common stock absent vs prior period); company sold LifeMD common stock during 2025
    • Income tax expense: $0.2M; effective tax rate negative 9.3% vs 246.8% in 2025; attributed to valuation allowance and discrete state tax items
    • Net loss: -$2.1M or -$0.19/share vs -$0.8M or -$0.07 diluted/share prior year
    • Cost savings target: anticipated >$30M future savings referenced under 3.0 strategy (COGS/SG&A allocation not quantified)

    AI IconCapital Funding

    • Cash, cash equivalents, and investments: ~$168.9M as of 03/31/2026 (no debt)
    • Working capital: $160.4M as of 03/31/2026; expected >$140M at 12/31/2026
    • No buyback or incremental debt activity mentioned

    AI IconStrategy & Ops

    • 3.0 strategy: strengthened clinical/scientific foundation and realigned cost structure expected to generate >$30M future savings
    • Shift focus from weight management as primary benefit to optimal metabolic health as primary benefit (weight remains key component)
    • New coach leadership structure comprised of executive director organizations; active earning coach decline linked to restructuring
    • Repeatable cadence of coach-led product and business opportunity meetings accelerated (above year-ago levels)
    • Completed coach incentive trip and Go Global event (well attended; reinforced field energy)
    • New metabolic system built around three phases: reset, refine, renew; new proprietary ingredient technology; pilot with small group of clients/coaches showed encouraging feedback
    • Company-led marketing reductions and one-time Maryland distribution center sale gain influenced SG&A leverage metrics

    AI IconMarket Outlook

    • Q2 2026 guidance: revenue $60M-$80M; loss per share -$0.50 to -$1.00
    • Full-year 2026 guidance: revenue $270M-$300M; loss per share -$1.05 to -$2.75
    • Profitability improvement timing: improvements to get back to profitability expected to begin in Q4 2026 following launch of the new product line; continued into 2027 and beyond
    • Coach productivity expected to continue growing during Q2 (YoY and sequentially)

    AI IconRisks & Headwinds

    • Rapid GLP-1 adoption continues to impact traditional weight loss category, driving lower active earning coaches (-44.9% YoY in Q1)
    • Revenue growth historically lags coach productivity by several quarters; management does not specify exact timing for return of absolute coach growth
    • Gross margin pressure persists due to fixed-cost leverage loss at lower sales volumes (gross margin -470 bps YoY in Q1)
    • No explicit guidance on gross margin/COGS or SG&A steady-state; management declined to provide specific gross margin breakout levels
    • Tax rate volatility risk given valuation allowance dynamics and discrete quarter items

    Q&A: Analyst Interest

    • Coach productivity drivers: Management explained +19% YoY coach productivity growth was not from higher average order sizes; average order sizes remained consistent. The increase came from more clients per coach and improved length of stay, supporting future revenue potential as coaches translate productivity into channel expansion.
    • Metabolic-health messaging in a GLP-1 environment: Management stressed weight-loss commoditization under GLP-1 and differentiated via quality of weight loss. They cited 14% visceral fat reduction and 98% lean mass preservation in 16 weeks, positioning metabolic synchronization as a comprehensive lifestyle system versus one-dimensional pharmacology.
    • Timing for coach growth and profitability: Management would not give exact quarter timing for when absolute coach counts return. They emphasized historical sequencing where productivity leads channel expansion, then provided context: sequential revenue growth implies stabilization, and Q4 2025 vs Q1 2026 revenue remained near-flat, suggesting near-term momentum without committing to a specific quarter.

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the MED Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    📋 Official Regulatory 10-K / 10-Q SEC Filings

    Direct authenticated documentation links to audited SEC database reports for MED.

    SEC EDGAR Live Feed
    Loading financial data and tables...
    📁

    SEC Filings (MED)

    © 2026 Stock Market Info — Medifast, Inc. (MED) Financial Profile